Navigation Links
Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
Date:4/19/2009

XMT-1107 inhibited human MetAP2 in vitro, was highly active in human umbilical vein endothelial cell (HUVEC) proliferation assays, and showed anti-angiogenesis activity in vivo in the Matrigel plug assay. Additionally, XMT-1107 was active in a number of syngeneic and xenograft tumor models. The enhanced antiangiogenic and in vivo anti-tumor activity of XMT-1107 compared to its in vivo release product XMT-1191 clearly demonstrated the benefit of conjugating XMT-1191 to Fleximer(R) and supports the potential clinical utility of XMT-1107 as an anti-cancer agent.

"Pharmacokinetics of a novel fumagillol conjugate XMT-1107 in the rat"

By Alex Yurkovetskiy, Dana L. Shkolny, Laura C. Akullian, Mao Yin, Laraine L. Meyers, Robert J. Fram, Timothy B. Lowinger.

This study evaluated the pharmacokinetics (PK) of XMT-1107 and its conjugate release product, XMT-1191, in rats. The XMT-1107 conjugate extended exposure to its corresponding drug release product, XMT-1191, while significantly reducing (> 500 fold) maximum XMT-1191 plasma levels (Cmax).

The data suggest that the slow rate of release of XMT-1191 from the polymer conjugate XMT-1107 provided a low but consistent exposure to the highly active XMT-1191 small molecule, providing an apparent half life of 22 hours compared with a half life of less than five minutes with free XMT-1191 administration. The data are consistent with the significantly higher in vivo activity seen for XMT-1107 relative to XMT-1191 in xenograft activity reported in a separate poster.

About Mersana Therapeutics, Inc.

Mersana, a privately held, venture backed company, utilizes its proprietary technology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. Mersana's lead compound, XMT-1001, is currently in Phase I trials in cancer patients. Mersana's secon
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Secondhand Smoke Quickly Affects Blood Vessels
2. Every 30 Seconds an African Child Dies from Malaria; Education Key to Prevention
3. Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009
4. Valensa Completes Second Expansion of Astaxanthin Capacity
5. Success of Colorful School Supply Collection Inspired by Leukemia Patient Kicks off Second Year
6. Metro Parents Second Annual Living With Autism Workshop Features Local Experts Who Are Intimately Involved in Improving the Lives of These Special Children
7. Equinox Fitness Clubs Continues National Expansion with the Opening of its Second Boston Location
8. Second European Radiosurgery Workshop Yields Record Attendance
9. Secondhand Smoke Affecting Millions of New Yorkers
10. Hillenbrand Expects to Report Second-Quarter Net Revenue of $170.8 Million and Revises 2009 Guidance
11. MoleSafe USA Opens Second Location in Albuquerque, New Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... found that the rates have increased among those who take the ... children immunized with the three-in-one MMR jab in Scotland. But the ... 95% by the age of two. But there was a 0.7% ... the vaccines association with the childhood autism disease. , ...
... decrease in chicken and egg prices have forced a Kolkata ... consuming pesticide. // The huge debts is said to have ... an owner of one of the biggest poultry farms in ... the chickens were found to be affected by Ranikhet disease. ...
... St. Louis say that a noninvasive approach towards assessing ... for cystic fibrosis and pneumonia. // Positron emission tomography ... in the lungs of healthy volunteers. ,"Until ... drug decreased lung inflammation, the options for specifically measuring ...
... group jogging or jogging with a friend will be more ... ,Researchers led by Professor Elizabeth Gould at Harvard University compared ... exercise in a group and found that contrary to accepted ... reported online edition of Daily Mail. ,The researchers ...
... bacteria belonging to the Legionella family, Legionella pneumophilia. // ... her 50s and the other in her 70s. They were ... , New South Wales (NSW) health officials are investigating an ... had been to the Chatswood's shopping area. The disease results ...
... record system, designed to connect up 50 million patients' records, ... trouble, according to reports. // The National Audit Office has ... rounds that the new NHS system might have thrown patients ... The switch to the new system, a modernization plan for ...
Cached Medicine News:
(Date:12/22/2014)... ALISO VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... moved into expanded corporate offices in Aliso ... President, announced that due to the tremendous growth and ... critically needed. Sales of patented SnoreRx, the anti snore ... administrative offices. He said, "We are now in ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 Swedish ... Inc. today announced that the Committee for Medicinal Products ... (EMA) has adopted a positive opinion for the use ... adult men with Peyronie,s disease with a palpable plaque ... the start of therapy. The use of ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... High-dose ursodeoxycholic acid detrimental for treatment of primary sclerosing cholangitis ... national team of researchers led by scientists at Mayo Clinic has ... liver disease, is not helpful for patients, according to a study ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090105/MAYOLOGO ...
... , ZURICH, Aug. 27 /PRNewswire/ -- ... of four phase III trials have been published in the prestigious peer-reviewed ... roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations ... COPD is an under-diagnosed progressive lung disease that may lead ...
Cached Medicine Technology:Researchers Find High-Dose Therapy for Liver Disease Not Effective 2Researchers Find High-Dose Therapy for Liver Disease Not Effective 3Researchers Find High-Dose Therapy for Liver Disease Not Effective 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 2Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 3Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 5Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 6Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 7Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 8Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 9
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: